MiNK Therapeutics Achieves Landmark Remission in Testicular Cancer Using AgenT-797

NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company, announced a significant breakthrough in cancer treatment. They published a case in Nature‘s Oncogene detailing complete remission in a patient with metastatic testicular cancer. The patient had previously failed multiple standard treatments, including platinum-based chemotherapy, autologous stem cell transplant, and various immune checkpoint inhibitors.

The groundbreaking publication describes a patient who participated in a clinical trial (NCT05108623) and received a single infusion of agenT-797, MiNK’s allogeneic invariant natural killer T (iNKT) cell therapy, along with nivolumab. Remarkably, the patient achieved complete clinical, radiologic, and biochemical remission, with no evidence of disease for over two years.

Dr. Benjamin Garmezy, Assistant Director of Genitourinary Research for Sarah Cannon Research Institute at SCRI Oncology Partners, commented on the findings. “This case exemplifies the powerful potential of iNKT cells in treating even the most challenging cancers,” he stated. “We observed a remarkable response in a patient who had exhausted standard and experimental treatments.”

The treatment was well-tolerated, with no reported cases of cytokine release syndrome (CRS) or graft-versus-host disease (GVHD). Donor iNKT cells were also detectable for up to six months post-infusion. These findings support the potential of agenT-797 in treating solid tumors and highlight its safety profile.

At the recent 2025 AACR Immuno-Oncology meeting, MiNK presented data from a Phase 2 trial in gastric cancer, showcasing immune activation and early signs of tumor control in patients who were previously resistant to checkpoint inhibitors. Several patients showed extended survival of more than 12 months following treatment.

A separate peer-reviewed case report in Oncogene noted that a different patient with metastatic gastric cancer achieved a 42% tumor reduction and over nine months of progression-free survival after receiving the same treatment.

The ongoing Phase 2 trial in gastric cancer (NCT06251973) is currently enrolling participants, with additional results expected in the coming months. MiNK Therapeutics continues to advance its innovative iNKT cell therapies, demonstrating their commitment to expanding treatment options for patients with difficult-to-treat cancers.